INTRODUCTION
The key determinants of general sleep-disordered breathing (SDB) related daytime drowsiness are unclear. Many candidate factors such as intermittent hypoxia, apnoea-hypopnoea index (AHI), sleep fragmentation, BMI, sleep time, and metabolic factors have been studied, but none show a strong correlation with daytime sleepiness. [1] [2] [3] [4] [5] [6] [7] [8] [9] Among those factors, relatively stronger evidence supports a role for oxygen desaturation index (ODI) or intermittent hypoxia in daytime sleepiness. 1, 2, 6 However, supplemental O 2 does not improve hypersomnolence in obstructive sleep apnea (OSA) patients despite improving oxygenation. [10] [11] [12] Similarly, O 2 therapy does not improve neurocognitive or psychosocial performances in hypoxemic, chronic obstructive pulmonary disease (COPD). 13, 14 In contrast, some human experimental studies suggest that hypercapnia can cause impaired mental and psychomotor function. [15] [16] [17] [18] While SDB is characterized by recurrent episodes of both hypoxia and hypercapnia, the relationship of hypercapnia to daytime sleepiness in this patient group has not been investigated. [1] [2] [3] [4] [5] This omission is likely due to the lack of clinical equipment to reliably measure continuous pCO 2 during the overnight PSG. However, in hypercapnic SDB patients particularly those with obesity hypoventilation syndrome (OHS) and overlap syndrome (COPD+OSA), a wide range of pCO 2 can be accurately measured during awake with arterial blood gas (ABG). Therefore this subtype of SDB patients could be an ideal patient group to investigate the relationship between hypoxia, hypercapnia and daytime sleepiness. Dose-dependent anesthesia-like effects of CO 2 have been previously reported. 19 In fact, CO 2 has long been used as a stunning agent to produce unconsciousness during porcine slaughter, while hypoxia does not produce this effect. 20 A clinical study found that untreated OSA patients have 4 | P a g e slower EEG compared to normal subjects which is not related to hypoxia. CPAP treatment corrected the EEG slowing together with reduced daytime sleepiness. 21 Recently we observed that respiratory failure patients have a paradoxically high percentage of slow wave sleep, and awake pCO 2 measured by ABG is the best predictor variable for the EEG change. 22 Furthermore, progressive hypercapnia but not hypoxia decreases EEG activation measured by an increased EEG Delta/Alpha (D/A) ratio. 23 Given these findings, we hypothesized that in hypercapnic SDB patients, the decrease in hypercapnia, but not hypoxia, is a key correlate for the improvement in daytime sleepiness, and may cross-correlate with changes in EEG spectral power, such as D/A ratio reflecting changes in EEG activation. 21, [24] [25] [26] We conducted an observational study using PAP treatment to test these hypotheses.
METHODS
The clinical study was conducted at the clinical sleep laboratory of Royal Prince Alfred Hospital (RPAH), a major teaching hospital of the University of Sydney. The study protocol was originally designed to test clinical outcomes of OHS patients receiving CPAP/BiPAP treatment over a 3-month period. Data of the present study come from post-hoc analyses of the original study. The 
Patients and Procedure
Study patients were consecutive patients recruited from the Sleep and Respiratory Failure Clinics of RPAH. We sampled late afternoon awake ABG in predominantly hypercapnic patients with severe SDB. Fifty-five OSA patients with either OHS or overlap syndrome (COPD+OSA) underwent two overnight PSGs before and after ~3 months Continuous/Bi-level Positive Airway Pressure (PAP) treatment. The recruited patients had daytime hypercapnia (arterial pCO 2 >45 mmHg) and/or frequent hypoventilation with significant oxygen desaturations during the initial diagnostic PSG studies. Hypoventilation was defined by an awake daytime pCO 2 > 45mmHg or during sleep a sustained fall in SpO 2 > 4% from baseline values accompanied by a rise in PtcCO 2 > 8mmHg. COPD was defined as FEV1/FVC ratio <70%, with severity based on percent of predicted FEV1 (GOLD criteria, www.goldcopd.com). We included both OHS and overlap syndrome patients considering that the effect of hypercapnia/hypoxia may share a common mechanism in affecting EEG and daytime sleepiness. Quantitative EEG spectral analyses were performed on the overnight PSG recordings. The Epworth Sleepiness Scale (ESS), a widely used measure of subjective daytime sleepiness was calculated in each patient. 27 
PSG
Overnight standard in-laboratory PSG was performed (between 10 pm and 7 am) using either [28] [29] [30] Respiratory events were scored according to Chicago criteria 29 , but no respiratory effort-related arousal events were marked. Sleep arousals were scored according to the American Sleep Disorder Association task force criteria. 30 AHI was calculated by dividing the total number of apnoeas and hypopnoeas by the total sleep time (hours). ODI was calculated by dividing the total number of SpO 2 dips by the total sleep time (hours).
EEG Spectral Analyses
We converted all EEG recordings to European Data Format for the spectral analyses. We analysed the EEG power spectra for each 5-second segment. To minimize blinking artefact in the EEG we encouraged all subjects to keep eyes open and stare at a relaxing picture on the wall during each testing session of the experimental study. In addition, we used subjects as their control to minimize behaviour confounders by comparing before-and-after intervention. All EEG study sampling rates were >200 Hz. A standard fast fourier transform with a rectangular weighting window was performed twice: first, to the largest power of 2 data points smaller than the total number of data points, selected from the beginning of the segment, and second, to the same number of data points selected from the end. This double fast fourier transform method weights middle-data-points. Delta, theta, alpha and beta bands were defined as the frequency ranges 0.5-4.5, 4. 
RESULTS
From the 55 patients tested, we obtained satisfactory data in 41 patients (30M, 11F, Aged 54.6 ± 12.8 years). Data were excluded due to either an unsatisfactory EEG quality for spectral analyses or failure to take blood for ABG in any phase of the study. Thirty two EEG spectra data were analyzed from C3/A2 channel and nine were analyzed from C4/A1 channel. Within these 41 patients, 26 had OHS and 15 had Overlap syndrome. Twenty-five patients received BiPAP treatment and 16 received CPAP treatment. The treatment option was allocated randomly as a part of the original study protocol in comparing the therapeutic outcomes of CPAP and BiPAP. Three 8 | P a g e patients were using O 2 supplementation during taking blood samples for ABG and during the initial diagnostic PSG. No patient had central apnea index > 5/hr either in baseline or after PAP treatment.
As shown in Table 1 , after ~3 months PAP treatment, patients showed a significant decrease in their waking pCO 2 , daytime sleepiness, as well as all key breathing/oxygenation parameters during sleep. BMI also decreased slightly. Similar to our previous report 31 , no difference was found between the options of CPAP and BiPAP in improving awake pCO 2 (p=0.27) and SpO 2 nadir during sleep (p= 0.62) in the present study. EEG spectral analyses showed that the D/A ratio of EEG was significantly reduced during both sleeping and waking periods, indicating a generally faster, more activated, EEG spectral profile following treatment (Table 2 ). There was also a reduction in High-Beta power (15-32 Hz) after the PAP treatment (Table 2 ). This reduction was correlated with the decrease in arousal index (r=0.33, p<0.05).
A cross-correlation was observed between a reduced wake pCO 2 , a faster (more-activated) EEG (reduced D/A ratio) and reduced daytime sleepiness (Table 3 , Figure 1 ). The cross-correlation pattern was similar between OHS and Overlap syndrome subtypes of patients as shown in Figure   1 . Specifically, there was a consistent pattern of positive correlations between the change of %Delta and ESS and pCO 2 ; and negative correlations between the change of %Alpha and ESS and pCO 2 ( Table 3 ). The ESS change also correlated significantly with waking pCO 2 change (r=0.42, p=0.007) (Figure 1 ). This pattern of the cross-correlations existed in both waking and sleeping periods of the PSG recordings ( Table 3 ).
Given that many related parameters such as hypoxia, hypercapnia, arousal index and BMI were improved after the PAP treatment ( 
DISCUSSION
We have demonstrated that hypercapnia but not hypoxia is a key correlate of both daytime sleepiness and EEG activation in patients with hypercapnic SDB. The decrease in hypercapnia was the best predictor of both reduction in daytime sleepiness and increase in EEG activation (reduced D/A ratio). We speculate that hypercapnia may cause daytime sleepiness through a reduction in brain activation in a hypercapnic SDB population.
SDB is usually associated with cyclic patterns of hypoxia and hypercapnia. In the present study, we demonstrated a significant cross-correlation between a reduced waking pCO 2 , a faster, more activated EEG spectral profile, and a reduced reported daytime sleepiness. Using multiple linear regression modeling, we demonstrated that hypercapnia accounted for more than double the variance of ESS compared to ODI (a measure of intermittent hypoxia frequency), and nearly 7 times the variance in EEG spectral (D/A ratio) compared to hypoxic severity. By contrast, hypoxia was not a significant predictor for the variance of ESS, although it is still a better predictor than AHI, arousal index, BMI and sleep efficiency.
We are not aware of any previous study showing hypercapnia as co-varying with hypersomnolence in any subtypes of SDB. [1] [2] [3] [4] [5] [6] [7] In the largest PAP intervention trial in sleep apnea, measures of hypoxia were only weakly associated with ESS, explaining <2% of the variance. The degree of hypercapnia in their study patients was unknown. 6 In another large study of determinants of sleepiness in 2882 OSA patients, 32 there was no real difference in hypoxia between those patients with or without sleepiness (only 1% difference). Interestingly, OSA patients with excess sleepiness had increased slow wave sleep compared to the non-sleepy patients, supporting a correlation between daytime sleepiness and a slower EEG spectral activity. 32 pCO 2 was not measured in this study. 32 Importantly, if hypoxia is a key factor in sleepiness, then hypersomnolence should be alleviated by giving supplemental O 2 . However, this prediction is not supported by the few relevant studies. [10] [11] [12] [13] Our notion that hypercapnia affects cerebral neural activity is supported by a number of experimental animal and human studies. Hypercapnia, acute or chronic, leads to the slowing of EEG in eels, 33 rats, 34 rabbits, 35 dogs 36 and monkeys. 37 In human experimental studies, hypercapnia led to slower EEG spectral activity with decreased alpha and beta activity [38] [39] [40] [41] [42] and increased delta activity 39 . A recent study tested the effects of mild hypercapnia (5% CO 2 ) on magnetoencephalogram, event-related potentials, auditory pattern recognition, and visual semantic tasks in 7 healthy volunteers. 41 Hypercapnia attenuated evoked and spontaneous magnetoencephalogram spectral activity. In addition, comparable decreases were observed in early sensory components in both auditory and visual modalities as well as cognitive components related to memory and language, and the depressant effects were distributed across all cortical regions. 41 Similarly, a few experimental studies reported dose-response relationship between higher CO 2 tensions and impaired cognitive and psychomotor performance. [15] [16] [17] In addition, breathing of CO 2 was reported to attenuate sensory and affective components of experimental ischemic pain and produce a dose-dependent elevation of heat pain threshold. 19 In this context, 80% CO 2 is commonly used as a porcine stunning agent to produce unconsciousness before slaughtering; hypoxia does not produce a similar anesthethetic effect. 20, 43 Given these data, exposure to sustained hypercapnia or possibly even brief bursts of intermittent hypercapnia in sleep-disordered breathing may result in drowsiness secondary to reduced brain neuro-electrical activation and overall depression of cortical activity.
In our studies, we used the Delta/Alpha ratio obtained from EEG spectral analyses as an objective marker of EEG activation which correlated to daytime sleepiness. An important consideration is that the D/A ratio can avoid the misinterpretation of an increased Delta power purely caused by a global, frequency independent, increase in EEG power. Ratios of slow and fast EEG frequency bands are commonly used in neurological studies to indicate activation of EEG. 21, [24] [25] [26] D/A ratio has been previously identified as the best discriminator between wake, and Stage 1, 2 and slow wave sleep, 26 and the best brain bio-marker correlating to the clinical outcomes of sub-acute ischemic stroke. 24 In the present study we only examined severe SDB patients with awake hypercapnia, so our findings may not apply to SDB patients in general, especially mild-moderate OSA patients, although the mechanism may play a role. To study the less severe SDB patients requires a fullyvalidated and accurate continuous measure of pCO 2 , fast enough to respond to the rapid changes due to respiratory events. Such a machine is currently not available. The commonly used transcutaneous pCO 2 (PtcCO 2 ) measurement are often affected by a drifting artefact, while a CO 2 analyzer connected to nasal cannula cannot sample expired air during a prolonged apnoea. We speculate that in milder SDB patients, the daytime hypersomnolence would be affected by the CO 2 mechanisms of 1) cyclic hypercapnia episodes during apnoea; 2) mild hypercapnia in daytime; and 3) SDB related chemoreflex changes particularly those CO 2 related factors such as CO 2 threshold.
Indeed, even in healthy individuals, average resting pCO 2 may vary largely, ranging from 32 to 44 mmHg. 44 There are a number of limitations to the study. This is not a prospective study originally designed to serve the purpose. The data were retrieved from post-hoc analyses of an interventional clinical study. Those patients were randomly allocated to BiPAP or CPAP treatment, thus the PAP treatment they were receiving might not be fully tailored to individual clinical conditions. There was still some residual SDB after PAP treatment. Three patients were using O 2 supplementation during blood sampling for ABG and during the initial diagnostic PSG which could affect pCO 2 and SpO 2
13 | P a g e results. In addition, most of our patients were taking different medications and it is not possible to obtain a medication free severe SDB patients group. Nevertheless, our study used patients as their own control, so that the effect of this potential confounding factor was minimized. Furthermore, our studies relied on self-reported measures of sleepiness. A further study using multiple sleep latency test or maintenance of wakefulness test to quantify daytime sleepiness in addition to ESS and EEG spectral analyses would be more definitive. Moreover, the sampling rate of our two PSG systems was slightly different, being 256 Hz for Compumedics and 200 Hz for Alice. Nevertheless, as the primary outcome of interest of the present study is Delta/Alpha Ratio (rather than an absolute spectral power) as an EEG activation marker, the potential confounding effect on our conclusion is therefore minimal. The last, it would be of interest to examine neuro-metabolic imaging during hypercapnia to clarify the relationship between hypercapnia, a slower EEG spectral profile and hypersomnolence.
In conclusion, we identified that in hypercapnic SDB population, hypercapnia is a key correlate of SDB-related daytime sleepiness, and there is a significant cross-correlation between the changes of hypercapnia, EEG spectral activity and daytime sleepiness. We speculate that hypercapnia may cause drowsiness through a reduced brain neuro-electrical activation in this population. Whether similar mechanisms also apply to less severe SDB patients without daytime hypercapnia deserve further investigation. 
